Anti-Human Sclerostin (SOST) (Romosozumab) - 100 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

SOST (sclerostin) is a secreted glycoprotein that acts as a negative regulator of bone growth viainhibition of Wnt signaling1. SOST functions by blocking LRP5/6 co-receptors and binding toLRP42. SOST is expressed in the developing embryo, where it is involved in limb patterning1.Dysregulation of SOST is associated with numerous diseases including postmenopausalosteoporosis2, osteoarthritis1, ankylosing spondylitis, and rheumatoid arthritis. Mutations arealso associated with inherited high bone mass conditions involving excessive bone formation, such as sclerosteosis, craniodiaphyseal dysplasia, and Van Buchem Disease2. SOST has alsobeen observed in bone tumors and bone cancer cell lines1. Monoclonal antibodies can be used totarget SOST and promote new bone formation. AMG 785 (Romosozumab) is a humanized monoclonal antibody against SOST that wasdeveloped for the treatment of osteoporosis3. Romosozumab was generated as a high-affinityPEGylated antibody fragment against SOST using the Selected Lymphocyte Antibody Method(SLAM) along with proprietary antibody fragment technologies. Scl-AbII is the murine IgG1SOST-neutralizing parent antibody. The humanized version Scl-AbIV induces a dose-dependentincrease in bone mineral density in cynomolgus monkeys4. Additionally, Romosozumab leads toincreased bone mineral density in humans5, 6, 7, 8.

≥ 5.0 mg/ml

SOST production at the protein level has been confirmed in osteocytes, osteosarcomas, osteoclasts, hypertrophic chondrocytes, articular cartilage-osteoarthritis, cementocytes, multiple myeloma (MM) patient CD138+ plasma cells and human MM cell lines, breast cancer cell line MDA-MB-231, prostate cancer, and aortic valves in areas adjacent tocalcification in hemodialysis patients.